Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 6/20 | 0.40 |
| ▸ | CA1 | P00915 | 6/20 | 0.40 |
| ▸ | CA2 | P00918 | 6/20 | 0.40 |
| ▸ | CA9 | Q16790 | 6/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31395584 | 0.98 | TDP1 (0.43) | TDP1MEN1GAAKMT2ACA12 | |
| SCHEMBL13759224 | 0.98 | TDP1 (0.43) | TDP1MEN1GAAKMT2ACA12 | |
| SCHEMBL21071149 | 0.98 | TDP1 (0.43) | TDP1MEN1GAAKMT2ACA12 | |
| SCHEMBL17739953 | 0.98 | TDP1 (0.43) | TDP1MEN1GAAKMT2ACA12 | |
| SCHEMBL15432864 | 0.98 | TDP1 (0.43) | TDP1MEN1GAAKMT2ACA12 | |
| SCHEMBL28656359 | 0.98 | TDP1 (0.43) | TDP1MEN1GAAKMT2ACA12 | |
| SCHEMBL31290234 | 0.94 | TDP1 (0.40) | TDP1MEN1GAAKMT2ACA12 | |
| SCHEMBL21070826 | 0.93 | CA12 (0.39) | TDP1MEN1GAAKMT2ACA12 | |
| SCHEMBL25835927 | 0.92 | TDP1 (0.38) | TDP1MEN1GAAKMT2ACA12 | |
| SCHEMBL23343285 | 0.91 | TDP1 (0.45) | TDP1MEN1GAAKMT2ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025105486-A1 | ANTIBODY-PHOTOSENSITIVE SUBSTANCE CONJUGATE | 第一三共株式会社 | 2025-05-22 | — | — | WO | disclosed |
| WO-2025082283-A1 | LIGAND COMPOUND OF CYCLOPEPTIDE STRUCTURE, NUCLIDE MARKER THEREOF, PHARMACEUTICAL COMPOSITION, AND USE | 四川科伦博泰生物医药股份有限公司 | 2025-04-24 | — | — | WO | disclosed |
| US-11807628-B2 | Benzodiazepine derivatives and uses thereof | INTOCELL, INC. (KR) | 2023-11-07 | — | — | US | disclosed |
| US-20230190939-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | INTOCELL, INC. (KR) | 2023-06-22 | — | — | US | disclosed |
| US-11065343-B2 | Compound bearing beta-galactoside-introduced self-immolative linker | INTOCELL INC. (KR) | 2021-07-20 | — | — | US | disclosed |
| US-20190328902-A1 | Compound Bearing Beta-Galactoside-Introduced Self-Immolative Linker | INTOCELL INC. (KR) | 2019-10-31 | — | — | US | disclosed |
| US-20150232616-A1 | HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS | INTEZYNE TECHNOLOGIES, INC. | 2015-08-20 | — | — | US | disclosed |
| US-8980326-B2 | Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents | INTEZYNE TECHNOLOGIES, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8952147-B2 | Conjugates, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2015-02-10 | — | — | US | disclosed |
| US-8952147-B2 | Conjugates, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2015-02-10 | — | — | US | disclosed |
| US-20100278932-A1 | POLYMER MICELLES CONTAINING SN-38 FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100278928-A1 | POLYMER MICELLES CONTAINING ANTHRACYLINES FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100278927-A1 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
| US-7799339-B2 | Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20100160645-A1 | POLY(ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS | INTEZYNE TECHNOLOGIES, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20090286938-A1 | SYNTHESIS OF HYBRID BLOCK COPOLYMERS FROM DIFLUOROACETATE AMMONIUM SALTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-7560588-B2 | Poly(ethylene glycol) containing chemically disparate endgroups | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20080274173-A1 | Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080207913-A1 | Poly(ethylene glycol) containing chemically disparate endgroups | INTEZYNE TECHNOLOGIES (US) | 2008-08-28 | — | — | US | disclosed |
| US-7230101-B1 | Synthesis of methotrexate-containing heterodimeric molecules | GPC BIOTECH, INC. (US) | 2007-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190939-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | CD47, ENPP2, CD2 | TDP1 2703/4885MEN1 1660/4885GAA 120/4885 |
| US-20100160645-A1 | POLY(ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS | GNE, EPRS1, ALG1 | TDP1 1487/4885MEN1 2092/4885GAA 142/4885 |
| US-11807628-B2 | Benzodiazepine derivatives and uses thereof | GABRB3, GABRB2, GABRB1 | TDP1 854/4885MEN1 3799/4885GAA 1121/4885 |
| US-11065343-B2 | Compound bearing beta-galactoside-introduced self-immolative linker | DDOST, B3GAT3, GALNT10 | TDP1 1893/4885MEN1 2690/4885GAA 61/4885 |
| US-20090286938-A1 | SYNTHESIS OF HYBRID BLOCK COPOLYMERS FROM DIFLUOROACETATE AMMONIUM SALTS | PFAS, GFPT1, PFKFB4 | TDP1 3790/4885MEN1 2965/4885GAA 967/4885 |
| US-20100278932-A1 | POLYMER MICELLES CONTAINING SN-38 FOR THE TREATMENT OF CANCER | MUC1, MSN, SNX9 | TDP1 2726/4885MEN1 339/4885GAA 2539/4885 |
| US-20100278927-A1 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | NCL, POLN, CHMP4B | TDP1 441/4885MEN1 677/4885GAA 1965/4885 |
| US-20190328902-A1 | Compound Bearing Beta-Galactoside-Introduced Self-Immolative Linker | DDOST, B3GAT3, GALNT10 | TDP1 1893/4885MEN1 2690/4885GAA 61/4885 |
| US-20100278928-A1 | POLYMER MICELLES CONTAINING ANTHRACYLINES FOR THE TREATMENT OF CANCER | ABCB4, TOP2A, ANXA5 | TDP1 1991/4885MEN1 337/4885GAA 1429/4885 |
| US-20080274173-A1 | Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery | CLTB, SLC1A5, CLTA | TDP1 3492/4885MEN1 2136/4885GAA 3481/4885 |
| US-20080207913-A1 | Poly(ethylene glycol) containing chemically disparate endgroups | GNE, EPRS1, ALG1 | TDP1 1487/4885MEN1 2092/4885GAA 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.